Taysha Gene Therapies Inc

$2.98 0.00% ($0.00)

Get ready to invest

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company. The Company is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

Popular Stocks	Price	Change
Nu Holdings NU	$4.33 13.35%	13.35%
Annaly NLY	$6.27 1.42%	1.42%
AMD AMD	$96.67 0.41%	0.41%
Nvidia NVDA	$171.24 1.1%	1.1%
SoFi Technologies, Inc. SOFI	$7.75 7.19%	7.19%
Ford F	$12.85 0.55%	0.55%
Apple AAPL	$137.35 2.46%	2.46%
Cisco CSCO	$41.72 13.73%	13.73%
Grab Holdings inc. GRAB	$3.14 24.11%	24.11%
NIO NIO	$16.66 5.24%	5.24%